微小RNA-223与消化系统肿瘤

doi:10.3760/cma.j.issn.1673-422X.2020.02.010

国际肿瘤学杂志 ›› 2020, Vol. 47 ›› Issue (2): 112-114.doi: 10.3760/cma.j.issn.1673-422X.2020.02.010

微小RNA-223与消化系统肿瘤

朱泽民, 谢智钦, 孙永康, 唐才喜()

中南大学湘雅医学院附属株洲医院肝胆胰脾外科 412007

收稿日期:2019-08-12 修回日期:2019-09-30 出版日期:2020-02-08 发布日期:2020-05-27
通讯作者: 唐才喜 E-mail:tcx0826@163.com
基金资助:
湖南省科技计划(2016SK4006);湖南省医药卫生科研计划(C2016109)

MicroRNA-223 and digestive system tumors

Zhu Zemin, Xie Zhiqin, Sun Yongkang, Tang Caixi()

Department of Hepatobiliary and Pancreatosplenic Surgery, Affiliated Zhuzhou Hospital of Xiangya School of Medicine, Central South University, Zhuzhou 412007, China

Received:2019-08-12 Revised:2019-09-30 Online:2020-02-08 Published:2020-05-27
Contact: Tang Caixi E-mail:tcx0826@163.com
Supported by:
Science and Technology Program of Hunan Province of China(2016SK4006);Medical and Health Research Program of Hunan Province of China(C2016109)

摘要/Abstract

摘要：

微小RNA-223(miR-223)定位于X染色体上,在进化过程中高度保守。近年来,许多研究指出miR-223在多种消化系统肿瘤如食管癌、胃癌、肝癌、胰腺癌、结直肠癌中表达异常,其可通过多种信号通路参与肿瘤细胞的增殖、凋亡、侵袭等过程,并有望成为消化系统肿瘤诊断和预后的标志物。

关键词: 微RNAs, 消化系统肿瘤

Abstract:

MicroRNA-223 (miR-223) is located on chromosome X, and is highly conserved in the process of evolution. In recent years, many studies have shown that miR-223 is abnormally expressed in a variety of digestive system tumors, such as esophageal cancer, gastric cancer, liver cancer, pancreatic cancer and colorectal cancer. MiR-223 can participate in the proliferation, apoptosis and invasion of tumor cells through a variety of signal pathways, which is expected to become a marker for the diagnosis and prognosis of digestive system tumors.

Key words: MicroRNAs, Digestive system neoplasms

朱泽民, 谢智钦, 孙永康, 唐才喜. 微小RNA-223与消化系统肿瘤[J]. 国际肿瘤学杂志, 2020, 47(2): 112-114.

Zhu Zemin, Xie Zhiqin, Sun Yongkang, Tang Caixi. MicroRNA-223 and digestive system tumors[J]. Journal of International Oncology, 2020, 47(2): 112-114.

参考文献 21

[1]	Rodriguez AE, Hernández JÁ, Benito R , et al. Molecular characterization of chronic lymphocytic leukemia patients with a high number of losses in 13q14[J]. PLoS One, 2012,7(11):e48485. DOI: 10.1371/journal.pone.0048485.
[2]	Roberto VP, Tiago DM, Gautvik K , et al. Evidence for the conservation of miR-223 in zebrafish (Danio rerio): implications for function[J]. Gene, 2015,566(1):54-62. DOI: 10.1016/j.gene.2015.04.022.
[3]	Ma J, Cao T, Cui Y , et al. miR-223 regulates cell proliferation and invasion via targeting PDS5B in pancreatic cancer cells[J]. Mol Ther Nucleic Acids, 2019,14:583-592. DOI: 10.1016/j.omtn.2019.01.009.
[4]	Komatsu S, Ichikawa D, Kawaguchi T , et al. Plasma microRNA profiles: identification of miR-23a as a novel biomarker for chemoresistance in esophageal squamous cell carcinoma[J]. Oncotarget, 2016,7(38):62034-62048. DOI: 10.18632/oncotarget.11500.
[5]	Fassan M, Saraggi D, Balsamo L , et al. Early miR-223 upregulation in gastroesophageal carcinogenesis[J]. Am J Clin Pathol, 2017,147(3):301-308. DOI: 10.1093/ajcp/aqx004.
[6]	陈蕾, 郑霭萱, 郑志伟 , 等. 食管鳞癌微小RNA-223表达临床意义研究[J]. 转化医学杂志, 2017,6(4):213-216. DOI: 10.3969/j.issn.2095-3097.2017.04.005.
[7]	Streppel MM, Pai S, Campbell NR , et al. MicroRNA 223 is upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1[J]. Clin Cancer Res, 2013,19(15):4067-4078. DOI: 10.1158/1078-0432.CCR-13-0601.
[8]	Yang F, Xu Y, Liu C , et al. NF-κB/miR-223-3p/ARID1A axis is involved in Helicobacter pylori CagA-induced gastric carcinogenesis and progression[J]. Cell Death Dis, 2018,9(1):12. DOI: 10.1038/s41419-017-0020-9.
[9]	李伦, 兴成娟, 丛玲 , 等. miR-223-3p靶向上皮细胞转化序列2基因调控胃癌细胞周期和凋亡的相关性研究[J]. 世界华人消化杂志, 2018,26(2):71-79. DOI: 10.11569/wcjd.v26.i2.71.
[10]	邓清, 张铁泉, 乐问津 , 等. 长链非编码RNA DRAIC调控miR-223对胃癌细胞迁移和侵袭的影响[J]. 西部医学, 2018,30(12):1753-1757. 10.3969/j.issn.1672-3511.2018.12.008.
[11]	王静, 吴兵, 沙莎 , 等. MicroRNA-223在胃癌患者血清中的表达及临床意义[J]. 临床消化病杂志, 2018,30(2):77-80. DOI: 10.3870/lcxh.j.issn.1005-541X.2018.02.03.
[12]	Wan L, Yuan X, Liu M , et al. miRNA-223-3p regulates NLRP3 to promote apoptosis and inhibit proliferation of hep3B cells[J]. Exp Ther Med, 2018,15(3):2429-2435. DOI: 10.3892/etm.2017.5667.
[13]	Tang X, Yang W, Shu Z , et al. MicroRNA223 promotes hepatocellular carcinoma cell resistance to sorafenib by targeting FBW7[J]. Oncol Rep, 2019,41(2):1231-1237. DOI: 10.3892/or.2018.6908.
[14]	孙宽学, 夏红卫 . miR-30e和miR-223在肝癌患者中的检测及临床意义[J]. 中国实验诊断学, 2018,22(9):1496-1500.
[15]	李丽敏, 秦雪 . miR-223在原发性肝癌患者血清中的表达及临床意义[J]. 广西医科大学学报, 2019,36(5):808-811. DOI: 10.16190/j.cnki.45-1211/r.2019.05.030.
[16]	Zhang R, Zhang LJ, Yang ML , et al. Potential role of microRNA-223-3p in the tumorigenesis of hepatocellular carcinoma: a comprehensive study based on data mining and bioinformatics[J]. Mol Med Rep, 2018,17(2):2211-2228. DOI: 10.3892/mmr.2017.8167.
[17]	He D, Huang C, Zhou Q , et al. HnRNPK/miR-223/FBXW7 feedback cascade promotes pancreatic cancer cell growth and invasion[J]. Oncotarget, 2017,8(12):20165-20178. DOI: 10.18632/oncotarget.15529.
[18]	Ma J, Zeng F, Ma C , et al. Synergistic reversal effect of epithelial-to-mesenchymal transition by miR-223 inhibitor and genistein in gemcitabine-resistant pancreatic cancer cells[J]. Am J Cancer Res, 2016,6(6):1384-1395.
[19]	Ju H, Tan JY, Cao B , et al. Effects of miR-223 on colorectal cancer cell proliferation and apoptosis through regulating FoxO3a/BIM[J]. Eur Rev Med Pharmacol Sci, 2018,22(12):3771-3778. DOI: 10.26355/eurrev_201806_15259.
[20]	Wang FF, Zhang XJ, Yan YR , et al. FBX8 is a metastasis suppressor downstream of miR-223 and targeting mTOR for degradation in colorectal carcinoma[J]. Cancer Lett, 2017,388:85-95. DOI: 10.1016/j.canlet.2016.11.031.
[21]	Chang PY, Chen CC, Chang YS , et al. MicroRNA-223 and microRNA-92a in stool and plasma samples act as complementary biomarkers to increase colorectal cancer detection[J]. Oncotarget, 2016,7(9):10663-10675. DOI: 10.18632/oncotarget.7119.

微小RNA-223与消化系统肿瘤

MicroRNA-223 and digestive system tumors

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 21

相关文章 15

编辑推荐

Metrics

本文评价

[1]	龚艳, 陈洪雷. 微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[2]	全祯豪, 徐飞鹏, 黄哲, 黄先进, 陈日红, 孙开裕, 胡旭, 林琳. 沉默lncRNA FTX通过miR-22-3p/NLRP3炎症体通路抑制胃癌细胞增殖[J]. 国际肿瘤学杂志, 2023, 50(4): 202-207.
[3]	周仁邦, 张仲传, 许志远, 朱勋兵. miR-219a-5p通过负调控HMGA2抑制骨肉瘤U2OS细胞增殖、侵袭和迁移[J]. 国际肿瘤学杂志, 2022, 49(4): 193-198.
[4]	金嘉会, 陈存海, 马学真. 放射相关miRNA在乳腺癌放疗中的作用[J]. 国际肿瘤学杂志, 2022, 49(12): 735-738.
[5]	井文君, 赵文文, 冯青青, 赵文飞, 赵丽丽, 张雪, 魏红梅. miR-34家族用于胃癌治疗的分子基础及临床前景[J]. 国际肿瘤学杂志, 2022, 49(11): 681-686.
[6]	徐凯, 文刚, 李瑞, 田园. 淋巴细胞与C反应蛋白比值对消化系统肿瘤预后价值的研究进展[J]. 国际肿瘤学杂志, 2022, 49(10): 627-629.
[7]	罗丽云, 赖灿辉, 梁仁佩, 杨爱武, 林志敏. 晚期胃癌中miR-524-5p与SOX9表达的相关性及其对化疗疗效和预后的影响[J]. 国际肿瘤学杂志, 2022, 49(1): 45-50.
[8]	刘佩, 蒲嘉泽, 黄雯, 汪斐. 吉非替尼敏感与耐药NSCLC患者miR-200c、miR-19a、miR-155表达差异及其对患者预后的影响[J]. 国际肿瘤学杂志, 2021, 48(7): 409-414.
[9]	王阳, 刘芊, 龙辉, 吴清明. 结直肠癌标志物粪便检测的研究现状[J]. 国际肿瘤学杂志, 2021, 48(7): 441-444.
[10]	居欣月, 胡春梅, 赵月, 唐艳. CDX2与胃肠道肿瘤[J]. 国际肿瘤学杂志, 2021, 48(6): 374-376.
[11]	程一鸣, 李刚, 王振明, 吕倩文, 李世荣. 血清miR-196a-5p、miR-105-5p在良恶性肺结节鉴别诊断中的价值[J]. 国际肿瘤学杂志, 2021, 48(5): 282-286.
[12]	邓波儿, 孔为民. 子宫内膜癌的表观遗传学研究进展[J]. 国际肿瘤学杂志, 2021, 48(3): 184-188.
[13]	李炳亮, 杨娅, 黄英丽, 司文, 李兴伟, 张元民, 卞继超, 陈语. miR-20a-5p靶向KDM6B对骨肉瘤细胞增殖、迁移和侵袭能力的影响[J]. 国际肿瘤学杂志, 2021, 48(2): 65-73.
[14]	刘培培, 杨梦雪, 严雪冰. m⁶A甲基化修饰在消化系统肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2021, 48(11): 688-692.
[15]	何苗, 范奎, 曹芳. 表观遗传与肺癌耐药[J]. 国际肿瘤学杂志, 2021, 48(10): 622-626.